AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 97 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $617,000 | – | 30,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 3,300,797 | $90,046,000 | 33.32% |
| Aisling Capital LLC | 1,990,000 | $54,287,000 | 11.73% |
| Foresite Capital Management III, LLC | 801,240 | $21,858,000 | 4.82% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 189,857 | $5,181,000 | 4.12% |
| AlpInvest Partners B.V. | 38,943 | $1,062,000 | 2.27% |
| Eventide Asset Management | 1,739,000 | $47,440,000 | 1.74% |
| Palo Alto Investors LP | 1,381,759 | $37,694,000 | 1.52% |
| Sofinnova Investments, Inc. | 222,295 | $6,064,000 | 0.54% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 553,000 | $15,086,000 | 0.54% |
| EMERALD ADVISERS, LLC | 486,666 | $13,276,000 | 0.49% |